Mobic Dosage Guide – Drugs.com

Print

Save

Generic name: MELOXICAM 7.5mg in 5mL
Dosage form: oral suspension
Drug class: Nonsteroidal anti-inflammatory drugs

Medically reviewed by Drugs.com. Last updated on Sep 5, 2022.

General Dosing Instructions

Carefully consider the potential benefits and risks of MOBIC and other treatment options before deciding to use MOBIC. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].

After observing the response to initial therapy with MOBIC, adjust the dose to suit an individual patient’s needs.

In adults, the maximum recommended daily oral dose of MOBIC is 15 mg regardless of formulation. In patients with hemodialysis, a maximum daily dosage of 7.5 mg is recommended [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

MOBIC oral suspension 7.5 mg/5 mL or 15 mg/10 mL may be substituted for MOBIC tablets 7. 5 mg or 15 mg, respectively.

Shake the oral suspension gently before using.

MOBIC may be taken without regard to timing of meals.

Osteoarthritis

For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of MOBIC is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

Rheumatoid Arthritis

For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of MOBIC is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

To improve dosing accuracy in smaller weight children, the use of the MOBIC oral suspension is recommended. MOBIC oral suspension is available in the strength of 7.5 mg/5 mL. For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of MOBIC is 0. 125 mg/kg once daily up to a maximum of 7.5 mg. There was no additional benefit demonstrated by increasing the dose above 0.125 mg/kg once daily in these clinical trials.

Juvenile Rheumatoid Arthritis dosing using the oral suspension should be individualized based on the weight of the child:

Renal Impairment

The use of MOBIC in subjects with severe renal impairment is not recommended.

In patients on hemodialysis, the maximum dosage of MOBIC is 7.5 mg per day [see Clinical Pharmacology (12. 3)].

Non-Interchangeability with Other Formulations of Meloxicam

MOBIC Suspension has not shown equivalent systemic exposure to other approved formulations of oral meloxicam. Therefore, MOBIC Suspension is not interchangeable with other formulations of oral meloxicam product even if the total milligram strength is the same. Do not substitute similar dose strengths of MOBIC Suspension with other formulations of oral meloxicam product.

Frequently asked questions

• Meloxicam vs Ibuprofen, what’s the difference?
• Can I take Meloxicam and Aleve or Tylenol together?
• Which painkiller should you use?
• Should I take meloxicam at night or in the morning?
• Can antidepressants be used for arthritis pain?
• How long do I wait after taking ibuprofen to take meloxicam?
• Is meloxicam very similar to Celebrex?
• Can meloxicam cause drowsiness and headache?
• Is meloxicam a narcotic?
• Is meloxicam helpful in gout treatment?
• Is meloxicam a sulfa drug?

More about Mobic (meloxicam)

• Check interactions
• Compare alternatives
• Reviews (133)
• Drug images
• Latest FDA alerts (5)
• Side effects
• During pregnancy
• Generic availability
• Support group
• Drug class: Nonsteroidal anti-inflammatory drugs
• Breastfeeding
• En español

Patient resources

• Drug Information
• Mobic (Meloxicam Suspension)
• Mobic (Meloxicam Tablets)

Other brands

Anjeso, Vivlodex, Qmiiz ODT

Professional resources

• Prescribing Information

Related treatment guides

• Osteoarthritis
• Rheumatoid Arthritis
• Juvenile Rheumatoid Arthritis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Mobic Interactions Checker – Drugs.com

Print

Save

There are 379 drugs known to interact with
Mobic (meloxicam), along with
12 disease interactions, and 3 alcohol/food interactions.

Of the total drug interactions,
95 are major, 278 are moderate, and 6 are minor.

Does Mobic interact with my other drugs?

Enter other medications to view a detailed report.

• View all 379 medications that may interact with Mobic
• View Mobic alcohol/food interactions (3)
• View Mobic disease interactions (12)

Most frequently checked interactions

View interaction reports for Mobic (meloxicam) and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• albuterol
• Ambien (zolpidem)
• aspirin
• Cymbalta (duloxetine)
• Flexeril (cyclobenzaprine)
• gabapentin
• hydrochlorothiazide
• Klonopin (clonazepam)
• levothyroxine
• Lexapro (escitalopram)
• Lipitor (atorvastatin)
• lisinopril
• Lyrica (pregabalin)
• metformin
• Neurontin (gabapentin)
• Nexium (esomeprazole)
• Norco (acetaminophen / hydrocodone)
• omeprazole
• prednisone
• Prilosec (omeprazole)
• Singulair (montelukast)
• Synthroid (levothyroxine)
• Topamax (topiramate)
• tramadol
• trazodone
• Vitamin B12 (cyanocobalamin)
• Vitamin D3 (cholecalciferol)
• Xanax (alprazolam)
• Zoloft (sertraline)
• Zyrtec (cetirizine)

Mobic alcohol/food interactions

There are 3 alcohol/food interactions with Mobic (meloxicam).

Mobic disease interactions

There are 12 disease interactions with Mobic (meloxicam) which include:

• asthma
• fluid retention
• GI toxicity
• rash
• renal toxicities
• thrombosis
• anemia
• heart failure
• hepatotoxicity
• hyperkalemia
• hypertension
• platelet aggregation inhibition

Report options

Loading…

QR code containing a link to this page

More about Mobic (meloxicam)

• Mobic consumer information
• Compare alternatives
• Reviews (133)
• Drug images
• Latest FDA alerts (5)
• Side effects
• Dosage information
• During pregnancy
• Generic availability
• Support group
• Drug class: Nonsteroidal anti-inflammatory drugs
• Breastfeeding
• En español

Related treatment guides

• Osteoarthritis
• Rheumatoid Arthritis
• Juvenile Rheumatoid Arthritis

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Major	Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate	Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor	Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown	No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Motrin® tablets 250 mg – 10 and 20 pieces for pain and inflammation up to 12 hours, prices

to <1/10), infrequently (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), frequency unknown (not can be estimated based on available data).

The most frequently observed adverse reactions were from the gastrointestinal tract. It is possible to develop a peptic ulcer, gastric perforation or gastrointestinal bleeding, sometimes fatal, especially in elderly patients (see section “Special Instructions”).

Within each group, HPs are listed in descending order of severity.

Blood and lymphatic system disorders:

Uncommon: Eosinophilia, granulocytopenia, leukopenia, thrombocytopenia.

Nervous system disorders:

often: headache, vertigo, dizziness, drowsiness;

infrequently: depression, sleep disturbance, impaired concentration, insomnia, malaise.

Visual disturbances:

common: visual impairment.

Hearing and labyrinth disorders:

often : tinnitus, hearing impairment;

Uncommon: hearing loss.

Cardiac disorders:

common: swelling, palpitations;

Uncommon: congestive heart failure.

Respiratory, thoracic and mediastinal disorders:

often : shortness of breath;

infrequently : eosinophilic pneumonia.

Gastrointestinal disorders:

often: constipation, abdominal pain, dyspepsia, nausea, diarrhoea, stomatitis, flatulence;

infrequently: gastrointestinal bleeding and / or gastric perforation, hematemesis, melena, vomiting;

very rare : relapse or worsening of ulcerative colitis or Crohn’s disease;

frequency unknown : gastritis.

Liver and biliary tract disorders:

infrequently: increased activity of “liver” enzymes, jaundice.

Skin and subcutaneous tissue disorders:

often : pruritus, skin rash, ecchymosis, purpura;

infrequently : alopecia, photodermatosis;

very rare : bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Musculoskeletal and connective tissue disorders:

infrequently : myalgia and muscle weakness.

Renal and urinary tract disorders:

Uncommon: glomerulonephritis, hematuria, interstitial nephritis, nephrotic syndrome, renal failure, renal papillary necrosis.

General disorders and administration site disorders:

often : thirst, increased sweating;

infrequently : hypersensitivity reactions, menstrual disorders, hyperthermia (chills and fever).

During therapy with non-steroidal anti-inflammatory drugs, edema and symptoms of heart failure, increased blood pressure were reported.